Platinum-based chemotherapy is a primary treatment for patients with advanced non-small cell lung cancer (NSCLC). Considering individual differences, an effective and convenient method is urgently needed to identify the sensitivity of individual patient to platinum based regimen. Genetic variants in DNA repair genes are presumed to represent important determinants of drug efficacy. Our previous studies have demonstrated the involvement of xeroderma pigmentosum group A (XPA) codon23 and xeroderma pigmentosum group D (XPD) codon751 single-nucleotide polymorphisms (SNPs) in clinical response to platinum based chemotherapy in advanced NSCLC patients. Thus, a follow-up study was carried out to investigate the relevance of these genotypes and survival of the cohort (n 5 115). The threedimensional (3-D), polyacrylamide gel-based DNA microarray method was used to assess the genotypes of XPA and XPD in peripheral lymphocytes. Log-rank test revealed that the variant genotypes of XPA23 (A/G1G/G) were associated with significantly longer progression-free survival (PFS) (6.0 m vs. 10.6 m, log-rank P 5 0.001) and overall survival (OS) (11.2 m vs. 20.8 m, log-rank P 5 0.001). In Cox proportional hazards model, the hazard ratio (HR) for death in patients with G allele was 0.65 (P 5 0.049). While no significant differences were observed in PFS or OS according to XPD Lys751Gln genotypes (log-rank P  0.05).
Introduction
Lung cancer is the leading cause of cancer-related death in many countries including China (1, 2) . Over one million people in the world die from the disease each year (3) . Non-small cell lung cancer (NSCLC) accounts for more than 80% of Technology in Cancer Research & Treatment, Volume 12, Number 5, October 2013 primary lung cancer and nearly two-thirds of NSCLC patients are at advanced stages at the time of diagnosis (4) . The survival of NSCLC is dismal with the survival rate of early stage remained only 40% (5) . Platinum-based chemotherapy is necessary to improve therapeutic response of NSCLC (6) . However, resistance to chemotherapy is truly a thorny problem. Mechanism of platinum resistance is considered to be related to DNA repair, decreased influx or increased efflux of drug, glutathione or metallothionein conjugation, drug detoxification, or skipping lesions during DNA replication (7) .
Drug resistance to chemotherapy varies from person to person, and genetic factors are believed to influence the chemotherapy response of lung caner (8) . The findings of Human genome project revealed that 99% of nucleotide sequences are identical within different individual and only 1% is variant, of which the major one is single nucleotide polymorphism (SNP). SNPs have been shown to alter the expression and function of corresponding genes (9) . Thus, SNPs in DNA repair genes are speculated to influence the efficacy of cancer treatment.
Platinum-based drugs predominantly inhibit tumor growth by the formation of bulky DNA adducts. This kind of DNA lesion is mainly removed by nucleotide excision repair (NER) which is one of DNA repair mechanisms. XPA (xeroderma pigmentosum group A) and XPD (xeroderma pigmentosum group D) are both DNA repairing related proteins which play key roles in the NER pathway. The XPA gene product is a kind of zinc-finger DNA-binding protein which is involved in both global genome and transcription-coupled repair pathway (10) . XPA is likely to play a central role in NER by recognizing the site of DNA damage and interacting with many core repair factors, e.g. transcription factor IIH (TF IIH), replication protein A, and excision repair cross-complementing group 1-xeroderma pigmentosum group F (ERCC1-XPF). XPD is a component of TF IIH and act as a DNA helicase which is mainly responsible for the repair of platinum-DNA adduct by removing a DNA segment along with its associated bulky adduct (11) .
In recent years, mounting evidence has proved that polymorphisms of genes involved in NER pathway including XPA and XPD were connected with response to platinumbased chemotherapy (12) (13) (14) (15) . The XPD lysine 751 glutamine polymorphism was reportedly associated with survival in NSCLC patients treated with platinum combined chemotherapy; however, studies thus far have yielded inconclusive evidence of an adverse effect of variant XPD751 genotype on survival (16) (17) (18) (19) . We have previously reported that XPA A23G polymorphism was identified to significantly increase the response to platinum-based chemotherapy, while no significant association was found between XPD polymorphism and treatment response (20, 21) .
In order to further investigate the correlation between the polymorphisms and patients' survival, we detected genotypes of XPA (A/G in codon 23) and XPD (A/C in codon 751) by use of a three dimensions (3-D) polyacrylamide gel-based DNA microarray in 115 advanced NSCLC patients who had received platinum-based chemotherapy and followed up for their progression-free survival (PFS) as well as overall survival (OS) to perform survival analysis.
Materials and Methods

Study Subjects
All patients were recruited from several medical institutions in Nanjing of China between March 2006 and September 2007. One hundred and fifteen advanced NSCLC patients diagnosed with histologically confirmed advanced NSCLC (stages IIIb-IV) and had a Karnofsky performance status of over 60 were enrolled in the study. Before treatment, blood test, hepatic and renal function and electrocardiogram of the patients were normal and thoracic computed scans with measurable lesion were examined. The study was approved by an Ethical Review Committee at the hospital and all patients gave their consent prior to their participation. The main characteristics of patients were displayed in Table I . (60°C) and extension for 40 s (72°C), and a last extension for 5 min at 72°C. PCR products were processed by ethanol precipitation, evaporation, or left untreated after PCR amplification and gel electrophoresis test. Solutions containing acryl-amide-modified PCR products, ammonium persulfate (APS), glycerol and acryl-amide monomers were prepared, spotted, and polymerized onto an acryl-modified slide. Meanwhile, the modified nucleic acids were immobilized by introduction of TEMED onto the spotted microarray. Following the attachment, dsDNA on the slides was denatured in 0.1 M NaOH for 10 min to obtain ssDNA for hybridization analysis. After hybridization, the slide was subjected to electrophoresis under 5-30 V/cm for 5-20 min in 1 Tris-Borate-EDTA (TBE) buffer at 4°C. Images of the slides were captured by a scanner (LuxScan TM -10 K Confocal Scanner, Packard BioScience Company, USA) and then analyzed with Genepix Pro 3.0 software. To validate the results from the 3-D DNA microarray, we performed sequencing of 10% samples randomly.
Statistical Analysis
Statistical analysis was performed using SPSS software package Version 13.0. Survival curves were plotted using the Kaplan-Meier method and compared with the log-rank test. The influence of genotype to progression-free and overall survival was estimated by computing the hazard ratios and their 95% confidence intervals from both univariate and multivariate Cox's regression models. All P values reported were 2-sided, and P values  0.05 were considered statistically significant.
Results
Images of DNA-Microarray Hybridization for SNPs Genotyping
Acryl-modified glass slides were selected to fabricate DNA microarrays, based on the immobilization efficiency. By allele-specific oligonucleotide dual-color fluorescence hybridization, homozygous wild type, homozygous mutant type and heterozygote type yielded green, red and yellow fluorescence, respectively.
Chemotherapy Regimens and Evaluation of Therapeutic Outcome
All patients received platinum-based chemotherapy, 50 (43.5%) were given TP/TC regimens (Taxol/Docetaxel1 DDP/CBP), 60 (52.2%) received GP/GC regimens (Gemcitabine1DDP/CBP) and 5 (4.3%) received NP/NC regimens (Vinorelbine1DDP/CBP) (Table I) . Concrete dosage: DDP 30 mg/m 2 on day 2-4; CBP AUC 5 4-5 g on day 1; Taxol 175 mg/m 2 on day 1 (kept for 3 hours) and docetaxel 60 mg/m 2 on day 1 (kept for 1 hour); vinorelbine 25 mg/m 2 on day 1 and day 8; gemcitabine 1 g/m 2 on day 1 and day 8. All chemotherapeutic drugs were administered intravenously, and treatment cycles were repeated every 3-4 weeks.
The patients were followed up every six weeks after the treatment. PFS was defined as the time between the onset of chemotherapy and the occurrence of progressive disease or death. OS was calculated from the onset of chemotherapy to the date of death or last clinical follow-up.
DNA Collection and Genotyping
Genomic DNA was extracted from pre-treatment peripheral blood provided by patients using QIAGEN DNA Mini Kit, China. The genotyping procedure involved polymerase chain reaction (PCR) and the three-dimensional (3-D) polyacrylamide gel-based DNA microarray method (23 Probes and primers were designed by Primer Premier 5.0 software as previously described (20, 21) . One of each pair primers was modified with acrylamide phosphoramidite (Acrydite TM ; Matrix Technologies, Hudson, USA) at 5′-terminal. Each couple of probes was respectively labeled with Cy3 or Cy5 fluorescent dyes at 5′-terminal (Table II) . The PCR reactions were performed in 30 ul reaction system containing 10 pmol primer and 50 ng genomic DNA. The reaction included an initial step for 5 min at 95°C, then 35-40 cycles of denaturing for 30 s (94°C), annealing for 30 s Ten percents of samples were randomly selected and subjected to sequencing. The result was 100% consistent with that of the genotyping, which indicate the reliablility of 3-D DNA microarray method.
SNP genotyping of XPA23 and XPD751
The genotype distributions of XPD Lys751Gln were followed Hardy-Weinberg equilibrium (P 5 0.76). While that of XPA A23G polymorphism were not consistent with the equilibrium (P < 0.05) and its allelic frequencies were comparable with those reported by Wu et al. (24) . No correlation was observed between genotype frequencies and clinical features or regimens (data not shown). The contribution of distinct clinicopathologic characteristics and chemotherapy regimens to short-term responses (i.e., CR, PR, SD and PD) were assessed based on WHO criteria and details can be found in our previously published articles (20, 21) .
Three patients were lost to follow-up, two withdrew from the study due to NSCLC-unrelated death and three were alive at the cut-off date. The information acquired from these cases was considered as censored data in statistics. The median progression-free survival and overall survival times were respectively 7.9 months (95% CI, 5.7-10.1 months) and 19.2 months (95% CI, 15.7-22.7) in the whole population. Survival analysis data based on the genotype of XPA A23G and XPD Lys751Gln are shown in Table III .
XPA A23G Genotype and PFS and OS
The median PFS was significantly longer in variant genotypes of XPA A23G (A/G1G/G) compared with the wild genotype (A/A) (10.6 months versus 6.0 months; log-rank test, P 5 0.001). As shown in Figure 1 , Kaplan-Meier survival estimates indicated that patients with the A/A genotype of XPA had a poorer PFS than those carrying AG/GG genotypes. Similarly, A/G and G/G genotypes were significantly favorable factors for overall survival in advanced NSCLC patients (log-rank test, P 5 0.001; Table III ). The 25%, 50% and 75% PFS and OS of the patients according to XPA A23G polymorphisms also confirmed the above results (Table IV) . Given that the effectiveness of therapy might be affected by treatment regimens, a subgroup analysis of chemotherapy regimen was performed to evaluate the association between XPA polymorphisms and NSCLC survival. The regimens of NP/NC and TP/TC are combined as a non-GP/GC regimen considering their common antitumor mechanism. The OS time was significantly longer in patients carrying G allele (A/G1G/G) than A/A homozygous allele in GP/GC subgroup (P 5 0.004). However, in non-GP/GC subgroup, the difference of OS is not statistically significant (P 5 0.091).
Univariate Cox regression analysis revealed that the hazard ratio (HR) for progression in patients with variant genotypes of XPA23 (A/G1G/G) was 0.51 (95% CI: 0.34-0.78); however, the difference became less significant after adjusting for potential confounders (adjusted HR 5 0.66; 95% CI 0.44-1.01). The risk of death for the patients was significantly lower in carriers with XPA variant genotype (A/G1G/G) even when adjusting for age, sex, smoking status, histology, performance status and chemotherapy regimens (adjusted HR 5 0.65; 95% CI, 0.43-0.99) (Table III) .
Subsequently, stepwise Cox regression analysis was used to evaluate independent prognostic factors associated with patient survivals in this study population. The homozygous wild genotype (A/A) of XPA23 accounted for poor prognosis as an independent prognostic factor (P 5 0.058 for PFS; P 5 0.055 for OS) and two additional variables (responders, ECOG PS) were also included in the regression model with a significance level of P  0.05 for entering and P 5 0.1 for removal from the model (Table V) .
XPD Lys751Gln Genotype and PFS and OS
The quartile PFS and OS of the patients are presented in Table IV . As shown in Figure 2 , patients with homozygous wild genotype of XPD 751 (A/A) had a slightly superior PFS to those with variant genotypes (A/C1C/C) while log-rank test did not show statistically significant difference (P 5 0.168) (Table III) . Neither have we found remarkable difference in OS between patients carrying A/A homozygote (19.9 months; 95% CI, 14.9-24.9 months) and A/C1C/C genotype of XPD751 (18.2 months; 95% CI, 13.34-23.06 months; log-rank test, P 5 0.301). In addition, when further stratified according to chemotherapy regimens, XPD 751 polymorphic variants still showed no effect on OS or PFS.
XPA 23 and XPD 751 polymorphisms and toxicity
Hematologic and gastrointestinal toxicity were evaluated in 102 patients. Thirty-five (34.3%) patients developed severe hematologic toxicity (grade 3 or 4). While 13 (12.7%) patients suffered from severe gastrointestinal toxicity (grade 3 or 4).
The incidence of severe hematologic toxicity was not significantly different in XPA A23G (OR 5 1.14; 95% CI, Table VI ).
Discussion
Non-small cell lung cancer is known to be a heterogeneous disease which is responsible for diversity outcomes displayed by patients with similar clinical and pathological features: some are cured; some suffer from recurrence or aggravation (19) . It is hard to obtain tumor tissues in the advanced cases on account of the difficulty in accurate and smooth resection of tumor using the routine setting. Therefore, identifying of minimally invasive biomarkers is warranted for more accurate prognostic and predictive assessment of NSCLC patients.
Platinum-based chemotherapy is still the backbone of treatment for advanced NSCLC and the efficacy tend to be similar whether the partner drug is paclitaxel, docetaxel or gemcitabine (25, 26) . Cytotoxicity from cisplatin and other platinum containing drugs is attributed to the formation of platinum-DNA (Plt-DNA) adducts which is mainly repaired by the NER pathway, one of the DNA repair mechanisms (27) . Clinical outcome measured as either tumor regression or survival, is better in patients with higher levels of Plt-DNA adducts (28, 29) . Therefore DNA repair capacity (DRC) represented by NER is closely associated with tumor response to platinum-based chemotherapy, which has been verified by the result from the study of Bosken et al. (30) . NER is a complex process that involves more than 16 proteins of which any genetically determined alteration may influence their expression or function and subsequently DNA repair capacity (31, 32) . Previous studies have demonstrated the correlation between gene polymorphisms involved in DNA repair and chemotherapy response (33, 34) . By means of testing peripheral blood, our team has already done some work in assessing the role of DNA repair gene polymorphisms including XPA and XPD in the 
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XPA is a key factor involved in the damage recognitioncomplex of NER. By means of RNA interference, Wu et al. (36) identified that specific inhibition of XPA mRNA led to a decrease of NER capacity, increase cisplatin IC50 value 10 fold and hence sensitize human lung adenocarcinoma cells to cisplatin. Thus, deficiency of XPA function is postulated to sensitize tumor cells to other drugs that cause DNA bulky lesions repaired by NER. The A  G variant appearing in the 5′ end of XPA non-coding region (rs1800975) is most widely studied in recent years. Several studies on the impact of the XPA A23G polymorphism on cancer susceptibility have been performed. A latest meta-analysis demonstrated that the G allele of XPA A23G is a low-penetrant risk factor for cancer development (37) . Nonetheless, the functional significance of the XPA A23G polymorphism remains largely inclusive, although it is deemed that this polymorphism modulates the sensibility to platinum-based chemotherapy via affecting capacity for bulky adducts removing. To our knowledge, no data to date are available regarding the impact of XPA A23G polymorphism on long-term outcomes of platinum-treated NSCLC patients. The present follow-up study indicated that the variant XPA allele might lead to favorable influence on survival in NSCLC patients treated with platinum drugs. This result was consistent with that of our previous study suggesting that XPA variant genotype could increase response to platinum chemotherapy (21) . Besides, subgroup analysis suggested a more significant association between the 751Gln allele and poor outcome in GP/GC group compared with non-GP/CP group. One potential explanation is that gemcitabine synergistically acts with platinum by increasing platinum-adduct formation when incorporated into DNA (38, 39) , resulting in more remarkable response to the alteration of NER capacity due to polymorphisms in DNA-repair genes.
Polymorphisms of XPD codon 751 are non-synonymous, leading to a change in the amino acid sequence of protein that subsequently affects different protein interactions and results in the expression of distinct phenotypes. In a functional study, Lunn et al. reported that the presence of XPD751 Lys/Lys increased the risk of sub-optimal DNA repair (40) , which was postulated to result in favorable influence on responses to platinum drugs via inefficient capacity for removing bulky adducts induced by therapeutic platinum (41) . The XPD751 Lys/Lys genotype has been shown to correlate with better response to platinum based chemotherapy in various cancer types (42) (43) (44) (45) . As a matter of fact, the exact function of XPD Lys751Gln SNP has not yet been completely clarified (46) (47) (48) . XPD 751 polymorphisms have been widely reported to be involved in the development of lung cancer (49) (50) (51) and a significantly elevated risk of XPD Lys751Gln polymorphism for never-smokers was detected in a recent meta-analysis (52) . However, no consensus has been reached on the relation of Lys751Gln variant with survival in NSCLC patients receiving platinum based regimen (13, 53) . Although lack of statistically significant difference probably due to a relatively modest sample size, the result of current study indicated a trend of longer survival in the A/A genotype carriers which was consistent with several previous studies (16, 54) . It partially confirmed the biological significance of XPD Lys751Gln polymorphism in repairing platinum induced DNA damage.
On the other hand, analysis of grade 3 or 4 hematologic or gastrointestinal toxicity has not revealed statistically significant association with the polymorphisms in DNA-repair genes associated with OS. The findings of previous studies in NSCLC and pancreatic cancer patients were similar to ours with respect to XPD codon 751 polymorphisms (53, 55, 56) . The negative results might be explained by the sample size that is not large enough to detect a small effect from SNPs of low penetrance, alternatively, due to exclusion of other DNA repair genes that might synergistically act with the analyzed genes in normal tissues.
In conclusion, the current study is a supplement to our previous ones by comparing the PFS and OS in NSCLC patients carrying varied genotypes of XPA and XPD. It showed that the polymorphic status of XPA (A23G) might be a promising ancillary marker for predicting not only treatment response but also long-term outcome in terms of PFS and OS in advanced stage NSCLC patients. The present study provided a rationale basis for the utility of a combination of gene SNPs in DNA repair pathway in predicting therapeutic effect. Considering the relatively small sample size of this study, a multicenter trial with a large sample size and following standardized randomized control design is warranted in the future to achieve adequate statistic power.
Although some traditional technologies including PCRrestriction fragment length polymorphism (RFLP), TaqMan assay and 5′ nuclease allelic discrimination assay are commonly used in many studies to detecting gene mutations or polymorphisms, their applications are limited in clinic owing to various defects. As for PCR-RFLP analysis, it possesses limitations such as the requirement of gene polymorphisms that alter a restriction enzyme cutting site, the complicated process and low throughput that is unable to identify all wanted genotypes in lager-scale genotyping (57). Despite identifying genetic polymorphisms rapidly and accurately, the main disadvantage of TaqMan assay is high cost in preparation of dual-labeled TaqMan probes. Therefore, in the present study we employed 3-D polyacrylamide gel-based DNA microarray, which has emerged as a cost-efficient way for new polymorphism detection. It is characterized by Technology in Cancer Research & Treatment, Volume 12, Number 5, October 2013 a 3-D porous structure which provides a higher capacity for nucleic acids immobilization and a solution-mimicking environment which enables an improvement in nucleic acids hybridization (58) (59) (60) (61) . Besides its high sensitivity and highthroughput, the average expense of individual sample is low and the testing process is relatively simple and fast. To our excitement, 3-D polyacrylamide gel-based DNA microarray is shown to be a more efficient and high-throughput technology in a large scale of genetic screening.
